The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | SLAMF7 as a target for multiple myeloma
Leo Rasche, MD, University of Arkansas for Medical Sciences, Little Rock, AR, gives an update on the role of elotuzumab, which targets SLAMF7, in the treatment of multiple myeloma and discusses the quality of SLAMF7 as a therapeutic target. Dr Rasche reports that SLAMF7 is highly expressed in samples from patients with extramedullary multiple myeloma, thus concluding that SLAMF7 is a promising target. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
